Public Health England

PHE Weekly National Influenza Report

Summary of UK surveillance of influenza and other seasonal Public Health respiratory illnesses

26 April 2018 – Week 17 report (up to week 16 data)

This report is published weekly on the <u>PHE website</u>. For further information on the surveillance schemes mentioned in this report, please see the <u>PHE website</u> and the <u>related links</u> at the end of this document.

Summary Community surveillance GP consultation rates | Hospitalisations | All-cause mortality | Microbiological surveillance

| Vaccination | International | Acknowledgements | Related links |

Summary

During week 16 (ending 22 April 2018), influenza continues to circulate with most indicators around baseline threshold levels.. The Department of Health has issued an <u>alert</u> on the prescription of antiviral medicines by GPs.

Community influenza surveillance

- Seven new acute respiratory outbreaks have been reported in the past 7 days compared to 15 in the previous week. Six outbreaks were from care homes, where one tested positive for influenza A(H1N1)pdm09. The remaining outbreak was from the Other settings category which tested positive for respiratory syncytial virus (RSV).
- Overall weekly influenza GP consultation rates across the UK
 - In week 16, the overall weekly influenza-like illness (ILI) GP consultation rate was 4.0 per 100,000 in England, compared to 7.6 per 100,000 in week 15. This is below the baseline threshold of 13.1 per 100,000 for this season. In the devolved administrations, ILI rates continued to decrease and are below baseline levels.
 - Through the Syndromic Surveillance systems, GP In Hours consultations for influenza like illness and NHS 111 calls for cold/flu continued to decrease and are similar to baseline levels.

Influenza-confirmed hospitalisations

- In week 16, there were 25 new admissions to ICU/HDU with confirmed influenza (one influenza A(H1N1)pdm09, five influenza A(H3N2), 15 influenza A(unknown subtype) and four influenza B) reported across the UK (87/144 Trusts in England) through the USISS mandatory ICU scheme with a rate of 0.07 per 100,000 for England, compared to 0.15 in the previous week. This is above the baseline threshold of 0.05 per 100,000 for the 2017/18 season.
- In week 16, there were 48 hospitalised confirmed influenza cases (two influenza A(H1N1)pdm09, 19 influenza A(H3N2), 13 influenza A(unknown subtype) and 14 influenza B) reported through the USISS sentinel hospital network (all levels of care) (17 NHS Trusts across England), with a rate of 0.70 per 100,000 compared to 1.16 per 100,000 in the previous week. This is above the baseline threshold of 0.56 per 100,000 for the 2017/18 season.
- o There were no new influenza admissions reported from the six Severe Respiratory Failure centres in the UK in week 16.

<u>All-cause mortality data</u>

- In week 12 2018, no statistically significant excess all-cause mortality by week of death was seen overall and by age group in England and Wales, through the EuroMOMO algorithm. In the devolved administrations, no statistically significant excess allcause mortality for all ages was observed in Scotland and Northern Ireland in week 16 2018.
- <u>Microbiological surveillance</u>
 - One sample tested positive for influenza (one influenza B) through the UK GP sentinel schemes, with an overall positivity of 20.0% in week 16 compared to 30.4% in week 15.
 - Sixty-eight detections were recorded through the DataMart scheme (38 influenza A(H3), 13 influenza A(unknown subtype), four influenza A(H1N1)pdm09 and 13 influenza B) with a positivity of 5.7% in week 16 compared to 10.6% in week 15, which is below the baseline threshold of 8.6%.

Vaccination

- Up to week 04 2018, in 96.9% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2017/18 influenza vaccine in targeted groups was: 48.7% in under 65 years in a clinical risk group, 47.1% in pregnant women and 72.4% in 65+ year olds. In 96.8% of GP practices reporting weekly to Immform, the provisional proportion of children in England who had received the 2017/18 influenza vaccine in targeted groups was: 42.6% in 2 year olds and 44.0% in 3 year olds.
- Provisional data from the fifth monthly collection of influenza vaccine uptake by frontline healthcare workers show 68.7% were vaccinated by 28 February 2018, compared to 63.4% vaccinated in the previous season by 28 February 2017.
- Provisional data from the fourth monthly collection of influenza vaccine uptake for children of school years Reception,1, 2, 3 and 4 age show the provisional proportion of children in England who received the 2017/18 influenza vaccine via school, pharmacy or GP practice by 31 January 2018 in targeted groups was as follows: 62.6% in children of school year Reception age (4-5 years); 60.9% in children of school Year 1 age (5-6 years); 60.3% in children of school Year 2 age (6-7 years); 57.5% in children of school Year 3 age (7-8 years) and 55.7% in children of school Year 4 age (8-9 years).
- Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2018 is available. The report provides uptake at national, Local Team (LT), Area Team (AT), Clinical Commissioning Group (CCG) and at Local Authority (LA) levels.
- WHO have published their recommendations for the composition of the 2018/19 northern hemisphere influenza vaccine.

International situation

Globally, influenza activity decreased in most of the countries in the temperate zone of the northern hemisphere, with exception
of Eastern Europe where activity continued to increase. In the temperate zone of the southern hemisphere, influenza activity
remained at inter-seasonal levels. Worldwide, influenza A and influenza B accounted for a similar proportion of influenza
detections.


Community surveillance

Seven new acute respiratory outbreaks were reported in the past 7 days.

Acute respiratory disease outbreaks

- Seven new acute respiratory outbreaks have been reported in the past 7 days compared to 15 in the previous week. Six outbreaks were from care homes, where one tested positive for influenza A(H1N1)pdm09. The remaining outbreak was from the Other settings category which tested positive for respiratory syncytial virus (RSV).

-Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and respscidsc@phe.gov.uk




Medical Officers of Schools Association (MOSA) & PHE surveillance scheme •

- Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2017/18 season, 21 MOSA schools have agreed to participate in the scheme, including a total of 7,575 boarders.

- The overall ILI rate (all boarders) for week 12 was 1.6 per 1,000 boarders compared to 1.5 per 1,000 boarders in week 11.

-Since week 40, 47 outbreaks have been reported from 14 MOSA schools, with a total of 251 ILI cases identified. Out of the 47 outbreaks, seven tested positive for influenza B, one outbreak was positive for influenza A(H3) and four outbreaks were negative for influenza and other respiratory viruses.

- If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.





FluSurvey •

- Internet-based surveillance of influenza-like illness in the general population is undertaken through the FluSurvey. A project run jointly by PHE and the London School of Hygiene and Tropical Medicine.

- The overall ILI rate (all age groups) for week 16 was 18.2 per 1,000 (42/2,306 people reported at least 1 ILI) (Figure 3) compared to 30.1 per 1,000 in week 15.

- If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.org.uk/en/accounts/register/ website for more information.





Back to top

Weekly consultation rates in national sentinel schemes

Back to top


In week 16, the overall weekly influenza-like illness (ILI) GP consultation rate continued to decrease and is below the baseline threshold. In the devolved administrations, ILI rates continued to decrease and are below baseline levels.

• GP ILI consultations in the UK

RCGP (England)

- The weekly ILI consultation rate through the RCGP surveillance was at 4.0 per 100,000 in week 16 compared to 7.6 per 100,000 in week 15. This is below the baseline threshold (13.1 per 100,000) (Figure 4*). By age group, the highest rates were seen in 75+ year olds (6.1 per 100,000) and <1 year olds (6.0 per 100,000).

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10) in a standardised approach across Europe. For MEM intensity threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-ukttclinical-surveillance-through-primary-care



<u>UK</u>

- In week 16, overall weekly ILI consultation rates across the countries of the UK decreased compared to the previous week and are all below their respective baseline thresholds (Table 1).

- By age group, the highest rates were seen in the 75+ year olds in Northern Ireland (9.6 per 100,000), 65-74 year olds in Wales (5.1 per 100,000) and in the 45-64 year olds in Scotland (14.2 per 100,000).

Table 1: GP ILI consultations in the UK for all ages with MEM thresholds applied*

| GP ILI | | | | | | | | | | | | | | Wee | k num | ber | | | | | | | | | | | | | |
|----------------------------------|------|------|-----|------|------|------|------|-----|-----|------|------|------|------|-------|-------|-------|------|------|------|------|------|------|------|-------------|------|------|-----|-----|-----|
| consultation rates (all ages) | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| England (RCGP) | 6.8 | 5.4 | 5.9 | 6.1 | 5.0 | 6.4 | 5.9 | 7.3 | 7.6 | 8.5 | 11.4 | 18.9 | 21.0 | 37.3 | 53.1 | 54.1 | 52.1 | 43.0 | 34.0 | 29.1 | 29.1 | 18.3 | 20.3 | 18.6 | 13.5 | 9.9 | 8.0 | 7.6 | 4.0 |
| Wales | 5.7 | 6.5 | 6.6 | 5.4 | 5.0 | 5.4 | 6.2 | 6.4 | 5.9 | 6.4 | 8.7 | 13.2 | 16.7 | 36.3 | 62.0 | 74.5 | 52.8 | 52.3 | 44.2 | 42.4 | 33.3 | 25.8 | 24.6 | 17.3 | 11.3 | 5.9 | 8.8 | 5.9 | 3.2 |
| Scotland | 10.0 | 15.3 | 8.3 | 10.8 | 12.4 | 11.7 | 10.3 | 9.1 | 9.4 | 18.4 | 32.5 | 40.3 | 44.9 | 107.2 | 113.9 | 102.1 | 82.3 | 45.5 | 30.3 | 39.4 | 35.1 | 28.5 | 24.9 | 26.4 | 18.7 | 9.4 | 9.5 | 9.4 | 8.3 |
| Northern Ireland | 3.4 | 3.9 | 3.7 | 3.3 | 4.0 | 3.6 | 4.5 | 5.3 | 4.0 | 8.2 | 10.1 | 20.7 | 22.7 | 52.6 | 65.2 | 52.1 | 44.2 | 29.0 | 30.6 | 25.2 | 23.6 | 16.7 | 18.3 | 18.3 | 13.0 | 11.7 | 6.0 | 6.5 | 5.3 |

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10), in a standardised approach across Europe. For MEM threshold values for each country, please visit: <u>https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care</u>

GP In Hours Syndromic Surveillance System (England)

-The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is at 3.3 per 100,000 in week 16 (Figure 5).

During week 16, GP In Hours consultations for influenza like illness and NHS 111 calls for cold/flu continued to decrease and are similar to baseline levels.

Figure 5 represents a map of GP ILI consultation rates in week 16 across England by upper tier Local Authorities (utLA), with influenza-like illness surveillance MEM thresholds applied.

ILI consultation rates presented for each utLA on the map should be interpreted in context of regional and national ILI activity; as MEM thresholds are calculated (based on previous influenza seasons from 2012/13 onwards) separately for each of the nine PHE centres and utLA rates are then compared to Centre-level thresholds only, therefore utLAs with higher background rates than the Centre may appear to have higher ILI activity.

-For further information, please see the syndromic surveillance webpage.




Figure 5: Map of GP ILI consultation rates in week 16

Influenza confirmed hospitalisations (provisional)


Back to top

In week 16 2018, there were 25 new admissions to ICU/HDU with confirmed influenza (one influenza A(H1N1)pdm09, five influenza A(H3N2), 15 influenza A(unknown subtype) and four influenza B) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (87 Trusts in England). There were 48 hospitalised confirmed influenza cases (two influenza A(H1N1)pdm09, 19 influenza A(H3N2), 13 influenza A(unknown subtype) and 14 influenza B) were reported through the USISS sentinel hospital network across England (17 Trusts).

 Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 16)

- In week 16, there were 25 new admissions to ICU/HDU with confirmed influenza (one influenza A(H1N1)pdm09, five influenza A(H3N2), 15 influenza A(unknown subtype) and four influenza B) reported across the UK (87/144 Trusts in England) through the USISS mandatory ICU scheme, with a rate of 0.07 per 100,000 compared to 0.15 per 100,000 in the previous week for England data (Figures 6 and 7), this is above the baseline impact threshold of 0.05 per 100,000. A total of six deaths were reported to have occurred in week 16 in the UK.

A total of 3,479 new admissions (243 influenza A(H1N1)pdm09, 438 influenza A(H3N2), 1,146 (influenza A(unknown subtype) and 1,652 influenza B) and 382 confirmed deaths have been reported in the UK since week 40 2017.





*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data

USISS sentinel weekly hospitalised confirmed influenza cases, England (week 16)

- In week 16, there were 48 hospitalised confirmed influenza cases (two influenza A(H1N1)pdm09, 19 influenza A(H3N2), 13 influenza A(unknown subtype) and 14 influenza B) reported from 17 NHS Trusts across England through the USISS sentinel hospital network, with a rate of 0.70 per 100,000 compared to 1.16 per 100,000 in the previous week (Figures 8 and 9), this is above the baseline impact threshold of 0.56 per 100,000.

A total of 9,699 hospitalised confirmed influenza admissions (639 influenza A(H1N1)pdm09, 1,954 influenza A(H3N2), 2,345 influenza A(unknown subtype) and 4,761 influenza B) have been reported since week 40 2017 via the sentinel scheme.





*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 6 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: <u>https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data</u> • USISS Severe Respiratory Failure Centre confirmed influenza admissions, UK (week 16)

- In week 16, there were no new influenza admissions reported from the six Severe Respiratory Failure (SRF) centres in the UK. Since week 40, a total of 59 laboratory confirmed influenza admissions (13 influenza A(H1N1)pdm09, six influenza A(H3N2), 14 influenza A(unknown subtype) and 26 influenza B) were reported from the SRFs for the season to date.

All-cause mortality data

All-cause death registrations, England and Wales

- In week 15 2018, an estimated 12,301 all-cause deaths were registered in England and Wales (source: <u>Office for</u> <u>National Statistics</u>). This is an increase compared to the 10,794 estimated death registrations in week 14 2018.

• Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland

- In week 12 2018 in England and Wales, no statistically significant excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group and subnationally (all ages), after correcting ONS disaggregate data for reporting delay with the standardised <u>EuroMOMO</u> algorithm. This data is provisional due to the time delay in registration; numbers may vary from week to week.

- In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Scotland and Northern Ireland in week 16 2018 (Table 2).


Table 2: Excess mortality by UK country, for all ages*

| Country | Excess detected in week 16 2018? | Weeks with excess in 2017/18 |
|------------------|----------------------------------|------------------------------|
| England | NA | 50-04 |
| Wales | NA | 52,02-03 |
| Scotland | × | 49-04,09 |
| Northern Ireland | × | 49,51-05,07 |

* Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold

* NA refers to data not available for this week

Figure 10: Weekly observed and expected number of all-cause deaths in 65+ year olds, with the dominant circulating influenza A subtype, England, 2013 to week 12 2018



Back to top

Microbiological surveillance


Back to top

In week 16 2018, one sample tested positive for influenza (one influenza B) through the UK GP sentinel schemes, with an overall positivity of 20.0% compared to 30.4% in week 15. Sixty-eight positive detections were recorded through the DataMart scheme (38 influenza A(H3), 13 influenza A(unknown subtype), four influenza A(H1N1)pdm09 and 13 influenza B) with a positivity of 5.7% in week 16 compared to 10.6% in week 15, which is below the baseline threshold of 8.6%.

Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations

-In week 16, one sample tested positive for influenza (one influenza B) through the UK GP sentinel schemes, with an overall positivity of 20.0% compared to 30.4% in week 15 (Figure 11).


Since week 40, a total of 1,608 samples (503 influenza A(H3), 39 influenza (unknown subtype), 118 influenza A(H1N1)pdm09 and 948 influenza B) tested positive for influenza through this scheme.





NB. Positivity (%) omitted when fewer than 10 specimens were tested

Respiratory DataMart System (England)

In week 16 2018, out of the 1,201 respiratory specimens reported through the Respiratory DataMart System, 68 samples (5.7%) were positive for influenza (38 influenza A(H3), 13 influenza A(unknown subtype), four influenza A(H1N1)pdm09 and 13 influenza B) (Figure 12), which is above the MEM baseline threshold for this season of 8.6%. This compares to 10.6% in week 15.The highest positivity for influenza by age group was seen in the 45-64 year olds at 8.3% in week 16 (Figure 13). The overall positivity for RSV was low at 1.4% in week 16. Rhinovirus positivity increased slightly from 10.9% in week 15 to 12.8% in week 16. Adenovirus and parainfluenza positivity decreased slightly at 3.4% and 5.3% respectively in week 16. Human metapneumovirus (hMPV) positivity remained low at 2.4% in week 16 (Figure 14).







*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 8.6% in 2017/18.

• Virus characterisation

PHE characterises the properties of influenza viruses through one or more tests, including <u>genome sequencing</u> (genetic analysis) and <u>haemagglutination inhibition (HI)</u> assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit (RVU) has characterised 1717 influenza viruses detected since week 37 (Table 3). Nine hundred and four influenza B viruses have been analysed; 897 were characterised as belonging to the B/Yamagata/16/88-lineage and 7 belonging to the B/Victoria/2/1987-lineage. All characterised B/Yamagata/16/88-lineage viruses to date are antigenically similar to B/Phuket/3073/2013, the influenza B/Yamagata-lineage component of the 2017/18 Northern Hemisphere quadrivalent vaccine. Three of the B/Victoria/2/87-lineage viruses is antigenically similar to B/Brisbane/60/2008, the influenza B/Victoria-lineage component of 2017/18 Northern Hemisphere trivalent and quadrivalent vaccines. Four influenza B viruses have been characterised where sequencing of the haemagglutinin (HA) gene shows they belong within genetic clade 1A of the B/Victoria lineage, in a subgroup characterised by deletion of two amino acids in the HA. These double deletion subgroup viruses are antigenically distinct from the 2017/18 N.hemisphere B/Victoria lineage vaccine component, with similar viruses having been identified in a minority of influenza B/Victoria lineage viruses in the 2016/17 season in the US and Norway, and since detected in low proportions in other countries, including in Europe.

Genetic characterisation of 559 A(H3N2) influenza viruses detected since late summer, showed that the majority belong to genetic subclade 3C.2a, with 146 belonging to a cluster within this genetic subclade designated as 3C.2a1. Eighteen viruses belonging to the genetic subclade 3C.3a were detected. The Northern Hemisphere 2017/18 influenza A(H3N2) vaccine strain A/HongKong/4801/2014 belongs in genetic subclade 3C.2a.

Of 254 A(H1N1)pdm09 influenza viruses characterised, those that have been genetically characterised all belong in the genetic subgroup 6B.1, which was the predominant genetic subgroup in the 2016/17 season and to date during the current season. Viruses antigenically analysed are similar to the A/Michigan/45/2015 Northern Hemisphere 2017/18 (H1N1)pdm09 vaccine strain.

| Virus | No. viruses characterised | | | | | | | | | |
|--------------------|---------------------------|--------------|----------------|-------|--|--|--|--|--|--|
| viius | Genetic and antigenic | Genetic only | Antigenic only | Total | | | | | | |
| A(H1N1)pdm09 | 84 | 78 | 92 | 254 | | | | | | |
| A(H3N2) | 24 | 535 | 0 | 559 | | | | | | |
| B/Yamagata-lineage | 193 | 420 | 284 | 897 | | | | | | |
| B/Victoria-lineage | 6 | 1 | 0 | 7 | | | | | | |

Table 3: Viruses characterised by PHE Reference Laboratory, 2017/18

Antiviral susceptibility

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A (H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

During the current 2017/18 season since week 40 2017, 174 influenza A(H3N2) have been tested for oseltamivir susceptibility; 169 are susceptible but five are resistant. Of 153 A(H3N2) viruses with zanamivir susceptibility testing data, 150 are susceptible and three are resistant. After de-duplication, 221 influenza A(H1N1)pdm09 virus have been tested for oseltamivir susceptibility and all but six were fully susceptible. One hundred and twenty-eight of the 221 influenza A(H1N1)pdm09 virus were also tested for zanamivir susceptibility and were all fully susceptible. Four hundred and seventy-six influenza B viruses have been tested for oseltamivir susceptible. Four hundred and sixty-one out of the 476 influenza B viruses have also been tested for zanamivir susceptibility and all but one was fully susceptible.

• Antimicrobial susceptibility


Table 4: Antimicrobial susceptibility surveillance in lower respiratory tract isolates, 12 weeks up to 22 April 2018, E&W

-Table 4 shows in the 12 weeks up to 22 April 2018, the proportion of all lower respiratory tract isolates of *Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus,* MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.


| Organism | Antibiotic | Specimens tested (N) | Specimens susceptible (%) |
|---------------|------------------------|----------------------|---------------------------|
| | Penicillin | 4322 | 90 |
| S. pneumoniae | Macrolides | 4780 | 84 |
| | Tetracycline | 4690 | 8 |
| | Amoxicillin/ampicillin | 19401 | 66 |
| H. influenzae | Co-amoxiclav | 21012 | 8 |
| | Macrolides | 6468 | |
| | Tetracycline | 20832 | 99 |
| S. aureus | Methicillin | 7619 | 9 |
| 0. 44/645 | Macrolides | 8271 | 6 |
| MRSA | Clindamycin | 494 | 43 |
| MINGA | Tetracycline | 649 | 81 |
| MSSA | Clindamycin | 4578 | 7 |
| MOGA | Tetracycline | 6417 | 9: |

Vaccination

- Up to week 04 2018 in 96.9% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2017/18 influenza vaccine in targeted groups was as follows (Figure 15):
 - o 48.7% in under 65 years in a clinical risk group
 - 47.1% in pregnant women
 - o 72.4% in 65+ year olds



- In 2017/18, all two- and three-year-olds continue to be eligible for flu vaccination, through their GPs. Up to week 04 2018 in 96.8% of GP practices reporting weekly to Immform, the provisional proportion of children in England who had received the 2017/18 influenza vaccine in targeted groups was as follows (Figure 16):
 - \circ 42.6% in 2 year olds
 - o 44.0% in 3 year olds



 Provisional data from the fifth monthly collection of influenza vaccine uptake by frontline healthcare workers show 68.7% were vaccinated by 28 February 2018 from 99.6% of all organisations, compared to 63.4% vaccinated in the previous season by 28 February 2017. The <u>report</u> provides uptake at national, NHS local team, "old" area teams and Trust-level.

- Provisional data from the fourth <u>monthly</u> collection of influenza vaccine uptake for children of school years Reception, 1,2, 3 and 4 age (from a sample of 96.7% of all Local Authorities in England) show the provisional proportion of children in England who received the 2017/18 influenza vaccine via school, pharmacy or GP practice by 31 January 2017 in targeted groups was as follows:
 - o 62.6% in children school year Reception age (4-5 years)
 - 60.9% in children school year 1 age (5-6 years)
 - o 60.3% in children school year 2 age (6-7 years)
 - o 57.5% in children school year 3 age (7-8 years)
 - 55.7% in children school year 4 age (8-9 years)
- Provisional data from the fourth <u>monthly</u> collection of influenza vaccine uptake in GP patients up to 31 January 2018 show that in 99.5% of all GP practices in England responding to the main GP survey, the proportion of people in England who received the 2017/18 influenza vaccine was as follows:
 - 48.9% in under 65 year olds in a clinical risk group
 - o 47.2% in pregnant women
 - 72.6% in 65+ year olds
- Provisional data from the fourth <u>monthly</u> collection of influenza vaccine uptake in GP patients up to 31 January 2018 show that in 99.3% of all GP practices in England responding to the child GP survey, the proportion of people in England who received the 2017/18 influenza vaccine was as follows:
 - o 42.8% in 2 year olds
 - \circ 44.2% in 3 year olds

International Situation

Back to top

Influenza activity decreased in most of the countries in the temperate zone of the northern hemisphere, with exception of Eastern Europe where activity continued to increase. In the temperate zone of the southern hemisphere, influenza activity remained at inter-seasonal levels. Worldwide, influenza A and influenza B accounted for a similar proportion of influenza detections.

• <u>Europe</u> updated on 20 April 2018 (Joint ECDC-WHO Europe Influenza weekly update)

In week 15/2018, overall influenza viruses continued to circulate in the Region with 266% of the individuals sampled from primary healthcare settings testing positive, while all countries reported low or medium intensity of activity of respiratory infections. Both influenza virus types A and B were co-circulating with the majority being type A viruses.

In week 15/2018, influenza activity was at variable levels across the region. Of 42 Member States and areas reporting on intensity, 4 reported medium intensity and 38 reported low intensity.

For week 15/2018, 169 (26%) of 661 sentinel specimens tested positive for influenza viruses; 66% were type A and 34% were type B. Of 82 subtyped A viruses, 62% were influenza A(H1N1)pdm09 and 38% A(H3N2). Of 22 type B viruses ascribed to a lineage, only 2 were B/Victoria, all others were B/Yamagata.

In week 15, the overall numbers of reported laboratory confirmed ICU cases continued to decrease, 76 laboratory-confirmed influenza-infected cases were reported, with the majority reported by the United Kingdom (71%). A total of 63 cases were reported from other wards, with the majority reported from Ireland (68%).

Since week 40/2017, type A influenza viruses have been detected in 52% and type B in 48% of cases in ICUs. Of 1 794 subtyped influenza A viruses, 59% were A(H1N1)pdm09 and 41% A(H3N2). Of 5 596 cases with known age, 45% were 15–64 years old and 48% were aged 65 years and older.

For week 15/2018, data from 22 countries or regions reporting to the <u>EuroMOMO</u> project were received and included in the pooled analyses of all-cause excess mortality. Mortality has been significantly elevated in a large number of European countries over the past weeks/months. Mostly elderly people have been affected. Mortality has now declined in most countries, but remains elevated in some.

An <u>early risk assessment</u> based on data from EU/EEA countries was published by ECDC on 20 December 2017. First detections indicated circulation of A(H3N2) and B/Yamagata viruses in the highest proportions. As the A(H3N2) subtype dominated last season, a high proportion of the population should be protected.

<u>United States of America</u> updated on 20 April 2018 (Centre for Disease Control report)

During week 15, influenza activity decreased in the United States.

Overall, influenza A(H3) viruses have predominated this season. Since early March, influenza B viruses have been more frequently reported than influenza A viruses. The percentage of respiratory specimens testing positive for influenza in clinical laboratories decreased.

A cumulative rate of 103.7 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported.

The proportion of outpatient visits for influenza-like illness (ILI) was 1.8%, which is below the national baseline of 2.2%.

• <u>Canada</u> updated on 20 April 2018 (Public Health Agency report)

Overall, during week 15, influenza activity in Canada continued to decrease, but many parts of the country are still reporting localized activity.

In week 15, detections of influenza A were greater than those of influenza B.

In week 15, 1.5% of visits to healthcare professionals were due to influenza-like illness; a decrease from the previous week.

To date this season, 4,835 influenza-associated hospitalizations were reported by participating provinces and territories. Among the hospitalizations, 3,260 (67%) were associated with influenza A, and 3,190 cases (66%) were in adults 65 years of age or older.

Additionally, 487 ICU admissions and 265 deaths have been reported to date. Adults aged 65 years of age or older accounted for the greatest proportion of ICU cases (44%), followed by adults aged 20-64 (39%). Adults aged 65 years of age or older accounted the majority of deaths (85%).

A <u>Canadian study</u> reported a mid-season estimate of influenza vaccine effectiveness of 42% overall. The study confirmed an anticipated low vaccine effectiveness of 17% against the A(H3N2) strain and moderate vaccine effectiveness against influenza B of 55%, which is circulating at high levels in Canada this season.

• <u>Global influenza update</u> updated on 16 April 2018 (WHO website)

Influenza activity decreased in most of the countries in the temperate zone of the northern hemisphere, with exception of Eastern Europe where activity continued to increase. In the temperate zone of the southern hemisphere, influenza activity remained at inter-seasonal levels. Worldwide, influenza A and influenza B accounted for a similar proportion of influenza detections.

Overall, influenza activity continued to decrease in North America. Influenza indicators continued to decrease in Canada and the United States of America (USA), with influenza B virus most frequently detected in the former and influenza A(H3N2) and influenza B viruses co-circulating in the latter.

Overall, influenza viruses continued to circulate widely in the European region, but most of the countries reported low to medium intensity. In Eastern Europe, influenza activity continued to increase with detections of influenza A and B viruses. In particular, influenza activity remained high in Latvia and the Russian Federation. In Northern and South West Europe, influenza A and B virus detections continued to decrease.

In Northern Africa, influenza activity decreased across most of the region, with the exception of Egypt where detections remained high.

In Western Asia, influenza activity appeared to decrease across the region, with all seasonal influenza subtypes present in the region. Detections of all seasonal influenza subtypes continued to be reported in Qatar. Decreased influenza virus detections were reported in Armenia, Israel, Lebanon and Saudi Arabia.

In Central Asia, influenza activity decreased across the region, although Kazakhstan reported high number of influenza detections in recent weeks.

In East Asia, influenza activity decreased across the region. In Northern and Southern China influenza detections continued to decrease, with influenza A(H1N1)pdm09 and influenza B viruses predominating.

In the Caribbean, influenza activity increased in general.

In the tropical countries of South America, influenza activities varied by countries.

In Western Africa, influenza activity remained low across the region.

In Southern Asia and South East Asia, low levels of influenza activity were reported across the regions.

The WHO GISRS laboratories tested more than 171,054 specimens between 19 March 2018 to 01 April 2018. 34,751 were positive for influenza viruses, of which 18,186 (52.3%) were typed as influenza A and 16565 (47.7%) as influenza B. Of the sub-typed influenza A viruses, 4,763 (62.7%) were influenza A(H1N1)pdm09 and 2,839 (37.3%) were influenza A(H3N2). Of the characterized B viruses, 1704 (91%) belonged to the B-Yamagata lineage and 169 (9%) to the B-Victoria lineage.

• <u>Avian Influenza</u> latest update on 02 March 2018 (WHO website)

Influenza A(H5) viruses

Between <u>25 January 2018 and 02 March 2018</u>, no new laboratory-confirmed human case of influenza A(H5) virus infection were reported to WHO.

Influenza A(H5) subtype viruses have the potential to cause disease in humans and thus far, no human cases, other than those with influenza A(H5N1) and A(H5N6) viruses, have been reported to WHO. According to reports received by the World Organisation for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

Influenza A(H7N4)

On <u>25 January 2018 and 02 March 2018</u>, one laboratory-confirmed human case of influenza A(H7N4) virus infection was reported to WHO from the Jiangsu province in China.

Influenza A(H7N9)

Between <u>25 January 2018 and 02 March 2018</u>, one new laboratory-confirmed human case of influenza A(H7N9) virus infection was reported to WHO from China.

Since 2013, a total of 1,567 laboratory-confirmed cases of human infection with avian influenza A(H7N9) viruses, including at least 615 deaths, have been reported to WHO.

Influenza A(H9N2)

Between <u>25 January 2018 and 02 March 2018</u>, three laboratory-confirmed human cases of A(H9N2) virus infection were reported to WHO from China.

Influenza A (H1N2)

On <u>20 March 2018</u>, the National International Health Regulations focal point for the Netherlands notified WHO about a human infected with a new reassortant A(H1N2) of seasonal influenza viruses that was detected in the routine sentinel influenza surveillance for influenza-like illness and other acute respiratory infections in the Netherlands.

• <u>Middle East respiratory syndrome coronavirus (MERS-CoV)</u> latest update on 25 April 2018

Up to 25 April 2018, a total of four cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (two imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 1,191 suspect cases in the UK that have been investigated for MERS-CoV and tested negative.

On <u>4 March 2018</u>, the National IRH focal point of Oman reported one additional case of Middle East respiratory syndrome coronavirus (MERS-CoV).

Between <u>9 December 2017 and 17 January 2018</u>, the National IHR Focal Point of The Kingdom of Saudi Arabia reported 20 additional cases of Middle East Respiratory Syndrome (MERS), including nine deaths. In addition, one death from a previously reported case was reported to WHO.

Globally, since September 2012, WHO has been notified of 2,143 laboratory-confirmed cases of infection with MERS-CoV, including at least 750 related deaths. Further information on management and guidance of possible cases is available <u>online</u>. The latest ECDC MERS-CoV risk assessment can be found <u>here</u>, where it is highlighted that risk of widespread transmission of MERS-CoV remains low.

Acknowledgements

This report was prepared by the Influenza section, Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance[®] and EMIS and EMIS practices contributing to the QSurveillance[®] database.

Related links

Back to top

Sources of flu data

- <u>Clinical surveillance through primary care in</u> the UK
- Outbreak reporting
- <u>FluSurvey</u>
- <u>MOSA</u>
- Real time syndromic surveillance
- MEM threshold <u>methodology paper</u> and <u>UK</u> <u>pilot paper</u>

Disease severity and mortality data

- USISS system
- EuroMOMO mortality project

Vaccination

- Seasonal influenza vaccine programme (Department of Health Book)
- Childhood flu programme information for healthcare practitioners (<u>Public Health England</u>)
- 2017/18 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)